BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26415374)

  • 1. Prognostic Value of Serum Free Light Chain in Multiple Myeloma.
    El Naggar AA; El-Naggar M; Mokhamer el-H; Avad MW
    Egypt J Immunol; 2015; 22(1):69-78. PubMed ID: 26415374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
    García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
    PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of serum free light chain in patients with multiple myeloma].
    Zhang SS; Wu S; Qu XY; Xu J; Liu P; Lu H; Wu HX; Xu JR; Li JY; Chen LJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):930-5. PubMed ID: 23998588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Free Light Chain Predict Overall Survival and Response to Therapy in Patients with Newly Diagnosed Multiple Myeloma.
    Meddour Y; Rahali MC; Belakehal SE; Ardjoun FZ; Chaib S; Djidjik R
    Clin Lab; 2018 Apr; 64(4):551-558. PubMed ID: 29739080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free κ to λ light chains.
    Xu Y; Sui W; Deng S; An G; Wang Y; Xie Z; Yao H; Zhu G; Zou D; Qi J; Hao M; Zhao Y; Wang J; Chen T; Qiu L
    Leuk Lymphoma; 2013 Jan; 54(1):123-32. PubMed ID: 22712834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Measurement of serum free light chains and its clinical significance in 20 newly diagnosed patients of multiple myeloma].
    Mao XB; Chen XQ; Zhai YP; Liang R; Gao GX; Ma GG; Yu YP; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):829-32. PubMed ID: 18718070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical Significance of Serum Free Light Chain and Its κ/λ Ratio in Patients with Multiple Myeloma].
    Zhao D; Jiang JQ; Lin L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1173-1178. PubMed ID: 31418375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust Reference Intervals for Serum Kappa and Lambda Free Light Chains from a Multi Centre Study Population from Hyderabad, India: Myeloma Diagnostic Implications.
    Mohammed N; Chandran PA; Kandregula M; Mattaparthi RD; Gundeti S; Volturi J; Darapuneni R; Raju SB; Dattatreya PS
    Asian Pac J Cancer Prev; 2016; 17(5):2605-10. PubMed ID: 27268638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of serum-free light-chain levels with markers of renal function.
    Erdem BK; Davran F; Yilmaz VT; Çetinkaya R; Akbas H
    Ren Fail; 2015 Jul; 37(6):1057-60. PubMed ID: 26056734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients.
    Yağcı M; Karakaya F; Suyanı E; Haznedar R
    Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):98-102. PubMed ID: 25441109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
    van Rhee F; Bolejack V; Hollmig K; Pineda-Roman M; Anaissie E; Epstein J; Shaughnessy JD; Zangari M; Tricot G; Mohiuddin A; Alsayed Y; Woods G; Crowley J; Barlogie B
    Blood; 2007 Aug; 110(3):827-32. PubMed ID: 17416735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay.
    Djidjik R; Lounici Y; Chergeulaïne K; Berkouk Y; Mouhoub S; Chaib S; Belhani M; Ghaffor M
    Pathol Biol (Paris); 2015 Sep; 63(4-5):210-4. PubMed ID: 26294067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of serum free light chain and its clinical significance in nonsecretory multiple myeloma].
    Chen HF; Hou J; Yuan ZG; Wang DX; Fu WJ; Chen YB
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):113-6. PubMed ID: 18681313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
    Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
    Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
    Özkurt ZN; Sucak GT; Akı ŞZ; Yağcı M; Haznedar R
    Cancer Invest; 2017 Mar; 35(3):195-201. PubMed ID: 28112977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma].
    Wang PF; Xu Y; Yan S; Yao Y; Zheng HF; Ma L; Jin S; Xu Y; Gong FR; Zhou JZ; Chang HR; Fu CC
    Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):377-82. PubMed ID: 27210871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.
    Kyrtsonis MC; Vassilakopoulos TP; Kafasi N; Sachanas S; Tzenou T; Papadogiannis A; Galanis Z; Kalpadakis C; Dimou M; Kyriakou E; Angelopoulou MK; Dimopoulou MN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Panayiotidis P; Pangalis GA
    Br J Haematol; 2007 May; 137(3):240-3. PubMed ID: 17408464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of Serum Free Light Chain on Renal Function and Prognosis in Patients with Newly Diagnosed Multiple Myeloma].
    Chen XD; Luo XF; Zu YP; Ye H; Li LL; Chen QL; Xie WZ; Yang T; Hu JD; Wei LX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Dec; 27(6):1862-1868. PubMed ID: 31839051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.
    Lopez-Anglada L; Cueto-Felgueroso C; Rosiñol L; Oriol A; Teruel AI; Lopez de la Guia A; Bengoechea E; Palomera L; de Arriba F; Hernandez JM; Granell M; Peñalver FJ; Garcia-Sanz R; Besalduch J; Gonzalez Y; Martinez RB; Hernandez MT; Gutierrez NC; Puerta P; Valeri A; Paiva B; Blade J; Mateos MV; San Miguel J; Lahuerta JJ; Martinez-Lopez J;
    PLoS One; 2018; 13(9):e0203392. PubMed ID: 30192814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
    Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
    Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.